VERV
Income statement / Annual
Last year (2024), Verve Therapeutics, Inc.'s total revenue was $32.33 M,
an increase of 174.98% from the previous year.
In 2024, Verve Therapeutics, Inc.'s net income was -$198.71 M.
See Verve Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$32.33 M |
$11.76 M |
$1.94 M |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$3.38 M
|
$1.33 M
|
$106.00 K
|
| Gross Profit |
$32.33 M
|
$11.76 M
|
$1.94 M
|
-$3.38 M
|
-$1.33 M
|
-$106.00 K
|
| Gross Profit Ratio |
1
|
1
|
1
|
0
|
0
|
0
|
| Research and Development Expenses |
$204.35 M
|
$184.95 M
|
$130.10 M
|
$68.20 M
|
$35.37 M
|
$11.14 M
|
| General & Administrative Expenses |
$56.65 M
|
$49.94 M
|
$37.53 M
|
$18.87 M
|
$5.26 M
|
$2.50 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$56.65 M
|
$49.94 M
|
$37.53 M
|
$18.87 M
|
$5.26 M
|
$2.50 M
|
| Other Expenses |
$0.00
|
$0.00
|
$1.49 M
|
-$33.39 M
|
-$5.24 M
|
$0.00
|
| Operating Expenses |
$260.99 M
|
$234.88 M
|
$167.63 M
|
$87.07 M
|
$40.63 M
|
$13.64 M
|
| Cost And Expenses |
$260.99 M
|
$234.88 M
|
$167.63 M
|
$87.07 M
|
$40.63 M
|
$13.64 M
|
| Interest Income |
$28.76 M
|
$23.17 M
|
$6.87 M
|
$142.00 K
|
$162.00 K
|
$278.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$6.75 M
|
$5.46 M
|
$6.71 M
|
$3.38 M
|
$1.33 M
|
$106.00 K
|
| EBITDA |
-$221.91 M |
-$217.67 M |
-$162.88 M |
-$85.53 M |
-$39.30 M |
-$13.54 M |
| EBITDA Ratio |
-6.86
|
-18.51
|
-83.92
|
0
|
0
|
0
|
| Operating Income Ratio |
-7.07
|
-18.98
|
-85.36
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$30.30 M
|
$23.33 M
|
$8.35 M
|
-$33.25 M
|
-$5.08 M
|
-$5.66 M
|
| Income Before Tax |
-$198.36 M
|
-$199.79 M
|
-$157.33 M
|
-$120.31 M
|
-$45.70 M
|
-$19.30 M
|
| Income Before Tax Ratio |
-6.14
|
-16.99
|
-81.06
|
0
|
0
|
0
|
| Income Tax Expense |
$349.00 K
|
$275.00 K
|
$53.00 K
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$198.71 M
|
-$200.07 M
|
-$157.39 M
|
-$118.64 M
|
-$45.54 M
|
-$19.02 M
|
| Net Income Ratio |
-6.15
|
-17.02
|
-81.09
|
0
|
0
|
0
|
| EPS |
-2.36 |
-3.12 |
-2.91 |
-2.45 |
-0.94 |
-0.65 |
| EPS Diluted |
-2.35 |
-3.12 |
-2.91 |
-2.45 |
-0.94 |
-0.65 |
| Weighted Average Shares Out |
$84.72 M
|
$64.18 M
|
$54.02 M
|
$48.51 M
|
$48.22 M
|
$29.17 M
|
| Weighted Average Shares Out Diluted |
$84.72 M
|
$64.18 M
|
$54.02 M
|
$48.51 M
|
$48.22 M
|
$29.17 M
|
| Link |
|
|
|
|
|
|
